Pfizer Inc. (PFE) Announces Results from the Phase 3 BASIS Study Evaluating HYMPAVZI

Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results from the Phase 3 BASIS study evaluating HYMPAVZI for adults and adolescents living with hemophilia A or B with inhibitors.

The results showed the superiority of HYMPAVZI for the improvement of bleeding outcomes in comparison with on-demand (OD) treatment with bypassing agents, reducing bleeds by 93% in adolescents and adults with hemophilia A or B with inhibitors. Management reported that HYMPAVZI was administered with a once-weekly subcutaneous injection that was straightforward and did not require extensive preparation or treatment-related lab monitoring.

“It is encouraging that these data demonstrate the potential of HYMPAVZI to combine efficacy, safety, and straightforward administration for adults and adolescents living with hemophilia A or B with inhibitors and address a significant patient need,” Michael Vincent, M.D., Ph.D., Chief Inflammation & Immunology Officer at Pfizer Inc. (NYSE:PFE), said regarding the situation. “We look forward to potentially making this treatment available for these patients as Pfizer continues its ongoing effort spanning more than 40 years to improve hemophilia care.”

Pfizer Inc. (NYSE:PFE) further stated that it submitted the data for review by the U.S. Food and Drug Administration and the European Medicines Agency. HYMPAVZI currently holds approval in over 40 countries as a treatment for eligible patients 12 years of age and older with hemophilia A or hemophilia B, without factor VIII inhibitors and without factor IX inhibitors, respectively.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.